State Board of Administration of Florida Retirement System maintained its position in CryoLife Inc. (NYSE:CRY) during the second quarter, Holdings Channel reports. The fund owned 46,069 shares of the company’s stock at the end of the second quarter. State Board of Administration of Florida Retirement System owned about 0.14% of CryoLife worth $544,000 at the end of the most recent quarter.
Other institutional investors have also recently bought and sold shares of the company. Louisiana State Employees Retirement System boosted its stake in CryoLife by 0.9% in the second quarter. Louisiana State Employees Retirement System now owns 11,400 shares of the company’s stock worth $135,000 after buying an additional 100 shares during the period. Arizona State Retirement System boosted its stake in CryoLife by 5.7% in the first quarter. Arizona State Retirement System now owns 13,054 shares of the company’s stock worth $140,000 after buying an additional 700 shares during the period. Adirondack Research & Management Inc. boosted its stake in CryoLife by 1.5% in the first quarter. Adirondack Research & Management Inc. now owns 277,123 shares of the company’s stock worth $2,979,000 after buying an additional 4,200 shares during the period. Prudential Financial Inc. boosted its stake in CryoLife by 11.8% in the first quarter. Prudential Financial Inc. now owns 65,404 shares of the company’s stock worth $703,000 after buying an additional 6,881 shares during the period. Finally, California State Teachers Retirement System boosted its stake in CryoLife by 22.3% in the second quarter. California State Teachers Retirement System now owns 66,083 shares of the company’s stock worth $780,000 after buying an additional 12,045 shares during the period. 58.13% of the stock is currently owned by hedge funds and other institutional investors.
CryoLife Inc. (NYSE:CRY) traded up 0.58% on Wednesday, hitting $17.39. 50,967 shares of the stock were exchanged. The firm has a market cap of $593.17 million, a P/E ratio of 55.74 and a beta of 1.05. The company has a 50-day moving average of $16.89 and a 200 day moving average of $13.36. CryoLife Inc. has a 12 month low of $8.94 and a 12 month high of $18.64.
CryoLife (NYSE:CRY) last posted its quarterly earnings results on Monday, July 25th. The company reported $0.13 EPS for the quarter, beating the Zacks’ consensus estimate of $0.02 by $0.11. CryoLife had a net margin of 5.80% and a return on equity of 8.15%. The firm had revenue of $47.10 million for the quarter, compared to analysts’ expectations of $35.50 million. During the same quarter in the prior year, the company posted $0.03 earnings per share. The business’s revenue for the quarter was up 32.6% on a year-over-year basis. Equities research analysts expect that CryoLife Inc. will post $0.34 earnings per share for the current fiscal year.
CRY has been the topic of a number of research reports. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $16.00 price target on shares of CryoLife in a report on Wednesday, July 27th. Lake Street Capital began coverage on shares of CryoLife in a report on Wednesday, June 15th. They set a “buy” rating and a $15.00 target price on the stock. Canaccord Genuity reissued a “buy” rating on shares of CryoLife in a report on Monday, June 20th. Finally, Zacks Investment Research raised shares of CryoLife from a “hold” rating to a “strong-buy” rating and set a $18.00 target price on the stock in a report on Friday, August 12th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $15.00.
In related news, Director C Elkins Ronald sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $14.00, for a total value of $28,000.00. Following the sale, the director now owns 103,586 shares in the company, valued at $1,450,204. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 6.08% of the stock is currently owned by corporate insiders.
CryoLife, Inc (CryoLife) is engaged in medical device manufacturing and distribution, and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment sells BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, Hemodialysis Reliable Outflow (HeRO) Graft, and ProCol Vascular Bioprosthesis (ProCol).
Want to see what other hedge funds are holding CRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CryoLife Inc. (NYSE:CRY).
Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.